As GLP-1 medications expand beyond weight management into cardiovascular disease, obstructive sleep apnea and now NASH, employers are entering uncharted territory. Each new indication brings pressure to extend coverage; yet doing so without a framework risks unsustainable costs and compliance pitfalls.

Sleep apnea is the perfect case study. It’s highly prevalent, 80% undiagnosed, often overlooked (especially in women), and already associated with comorbidities such as diabetes, hypertension, stroke and obesity, as well as productivity, disability, and safety risks. Proven treatments like CPAP and oral appliances remain the gold standard, but GLP-1s are now part of the conversation.

Join Mercer and Resmed on September 30th for a 60-minute webinar where our subject matter experts will:

• Examine the GLP-1 pipeline and the employer cost exposure if every new indication is covered.
• Explore the real impact of sleep apnea on today’s workforce and review effective, lower-cost treatment options.
• Share a compliance attorney’s perspective on how to design benefits programs that are equitable, non-discriminatory, and aligned with regulatory expectations.
• Offer Mercer’s practical framework for balancing employee health needs with fiscal responsibility.

Key takeaway: Employers can’t cover everything. But with the right strategy, you can support your people while protecting your plan.

CEO, CHRO, Human Resources, Benefits Managers, Total Rewards, Global Benefits, Global Compensation, Compensation Analyst, Benefits Advisor, Risk Management.